Importantly, the strongest data supporting kisspeptin as a trigger derive from early-phase trials in women at high risk of OHSS, showing high oocyte maturation rates and an excellent safety profile but still limited information on live birth and long-term outcomes. The gene discussed is KISS1; the disease is ovarian hyperstimulation syndrome.